Ligand Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Invesco Ltd. has disclosed beneficial ownership of 6.1% of Ligand Pharmaceuticals Inc.'s common stock as of June 30, 2026.
NASDAQ
The Vanguard Group reports 0% beneficial ownership of Ligand Pharmaceuticals Inc. common stock following an internal realignment.
NASDAQ
Janus Henderson Group plc has reported a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated common stock as of September 30, 2025.
NASDAQ
BlackRock, Inc. has filed an Amendment No. 18 to Schedule 13G, disclosing a beneficial ownership of 14.5% in Ligand Pharmaceuticals Inc. common stock.
NASDAQ
Janus Henderson Group plc has filed an Amendment No. 8 to its Schedule 13G, disclosing a 5.5% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: Janus Henderson Group PLC Amends Stake in Ligand Pharmaceuticals, Maintains Over 5% Beneficial Ownership
Janus Henderson Group PLC has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.3% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Janus Henderson Group PLC Updates Stake in Ligand Pharmaceuticals, Holding 5.4% of Common Stock
Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 5.4% beneficial ownership stake in Ligand Pharmaceuticals Incorporated as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Stake in Ligand Pharmaceuticals to 15.6%
BlackRock, Inc. has disclosed an increased beneficial ownership stake of 15.6% in Ligand Pharmaceuticals Inc., holding 2,945,939 shares as of December 31, 2024.